Pfizer and OPKO Health Announce FDA Approval of Ngenla for Pediatric Growth Hormone Deficiency

Gelonghui June 28th丨Pfizer, Inc. and OPKO Health, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved their drug for treating growth hormone deficiency in children. In January last year, the FDA rejected the drug. This injectable hormone, marketed under the brand name Ngenla, has been approved for pediatric patients over the age of 3 and is expected to be available in the U.S. in August.